Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
11,824
Total Claims
$518K
Drug Cost
496
Beneficiaries
$1,044
Cost/Patient
Risk Score Breakdown 13/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
-90%
Opioid rate vs peers
0.3% vs 2.6% avg
-2%
Cost per patient vs peers
$1,044 vs $1,068 avg
+21%
Brand preference vs peers
10.8% vs 9.0% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
0.3%
Opioid Rate
30
Opioid Claims
$121
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 1,273 claims · $376K
Generic: 10,466 claims · $140K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Insulin Glargine,hum.Rec.Anlog | 76 | $52K |
| Levothyroxine Sodium | 380 | $28K |
| Rivaroxaban | 36 | $28K |
| Insulin Lispro Protamin/Lispro | 29 | $23K |
| Sitagliptin Phos/Metformin Hcl | 19 | $20K |
| Sitagliptin Phosphate | 28 | $20K |
| Insulin Nph Hum/Reg Insulin Hm | 34 | $17K |
| Apixaban | 26 | $17K |
| Empagliflozin | 22 | $17K |
| Budesonide/Formoterol Fumarate | 38 | $16K |
| Insulin Lispro | 28 | $13K |
| Empaglifloz/Linaglip/Metformin | 13 | $7,884 |
| Candesartan/Hydrochlorothiazid | 38 | $7,294 |
| Losartan Potassium | 324 | $6,680 |
| Empagliflozin/Linagliptin | 11 | $6,675 |
Prescribing Profile
Patient Profile
72
Avg Age
57%
Female
1.95
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About